Vascular occlusion after hyaluronic acid filler injection is estimated to occur in roughly 1 in 5,000 injections, according to a ten-year retrospective review of 1.7 million syringe injections (Alam et al., JAMA Dermatology, 2021). That statistic sounds rare — until a practice treats 50 filler patients per week and the front desk calls back with a patient whose nose is turning white and cold three hours after a nasal-bridge injection.
Hyaluronidase dissolves hyaluronic acid. It is the only agent that can reverse a filler-induced vascular occlusion caused by HA product. But having a vial in the refrigerator is not the same as having an emergency protocol that works under pressure. This article covers what belongs in the kit, how to keep it stocked, how to drill it, and how to document it.
The Pharmacology That Drives Kit Design
Hyaluronidase is an enzyme that depolymerizes hyaluronic acid. In the United States, the only FDA-approved recombinant human hyaluronidase is Hylenex (hyaluronidase human injection), supplied as 150 USP units per mL in single-use vials.
In the United Kingdom, EU, and many other markets, hyaluronidase is commonly supplied as Hyalase at 1,500 units per vial. This tenfold difference in available concentration has practical implications for U.S. practices: more vials are needed to reach therapeutic doses.
The Complications in Medical Aesthetics Collaborative (CMAC) publishes the most widely referenced guideline for hyaluronic acid filler-induced vascular occlusion management. CMAC recommends:
- Initial dose: 1,500 units of hyaluronidase reconstituted with 1 mL of bacteriostatic saline 0.9% or 1%–2% lidocaine, infiltrated over the course of the affected artery and the wider area of ischemia.
- Re-dosing: If capillary refill has not been restored after 15–20 minutes, administer additional hyaluronidase. Repeat at hourly intervals for up to four cycles if vascular compromise persists.
- Treat to effect: CMAC emphasizes that treating to clinical effect is more reliable than fixed dosing. The clinician should focus on achieving full tissue coverage rather than counting units.
For a U.S. practice using Hylenex at 150 units per vial, an initial dose of 1,500 units requires 10 vials. A single vascular occlusion event with re-dosing could consume 20–40 vials. A practice that stocks only 2–3 vials is not emergency-ready.
Recommended Kit Inventory
A hyaluronidase emergency kit for HA filler vascular occlusion should contain:
Medications
- Hyaluronidase (Hylenex): Minimum 10 vials (1,500 units total). Practices that inject in high-risk areas — nose, tear troughs, temporal region, glabella — should stock 20–30 vials. A Doctor of Nursing Practice project on vascular occlusion protocol compliance recommended 30 vials per kit as best practice.
- Aspirin 325 mg tablets: For oral administration to support anticoagulation in the microvasculature. Not all protocols include this; CMAC does not list it as a primary intervention, but some practitioners include it as an adjunct.
- Nitroglycerin paste 2%: Topical vasodilator. Controversial — CMAC's guideline does not recommend nitroglycerin paste as a primary treatment, noting limited evidence. Some practitioners still include it for external vasodilation support.
- Epinephrine auto-injector (EpiPen): For anaphylaxis secondary to hyaluronidase administration. CMAC advises against performing allergy skin testing during a vascular occlusion emergency because time is critical, and recommends having epinephrine available instead.
Supplies
- 3 mL and 5 mL syringes (multiple).
- 18G needles for drawing.
- 25G 1.5-inch needles for injection.
- 27G or 30G needles for precise infiltration.
- Aesthetic cannulas (25G or 27G) — useful for infiltrating hyaluronidase along the affected vessel track.
- Alcohol swabs and skin disinfectant.
- Sterile saline 0.9% for reconstitution.
- Bacteriostatic saline 0.9% or 1%–2% lidocaine without epinephrine (for reconstitution per CMAC protocol).
- Warm compresses or disposable chemical heat packs (HotHands-style).
- Sterile gloves.
- Marking pen to outline the ischemic area for photography and monitoring.
- Timer or clock visible to the provider.
Documentation
- Printed copy of the practice's vascular occlusion protocol — laminated or in a protective sleeve.
- Emergency contact list: medical director, nearest ophthalmologist, nearest emergency department, nearest hyperbaric oxygen facility.
- Incident documentation form.
- Patient handout for post-occlusion monitoring.
Storage and Expiration Management
Hyaluronidase has specific storage requirements and a limited shelf life. The kit must be actively managed, not assembled once and forgotten.
- Storage temperature: Hylenex should be stored at 2°C to 8°C (36°F to 46°F). It should not be frozen. This means the kit — or at minimum the hyaluronidase component — must be stored in a medication refrigerator, not at room temperature.
- Expiration tracking: Every vial has an expiration date printed on the label. The person responsible for the kit should check expiration dates on a fixed schedule — monthly at minimum — and replace any vials within 30 days of expiration.
- Kit check log: A dated and initialed log confirming that the kit was checked, all components are present, no items are expired, and no items were used since the last check. This log is the practice's evidence that the kit was emergency-ready on any given day. After a vascular occlusion event, the question "was your emergency kit stocked and current?" will be asked. The log answers it.
- Post-use restocking: Any time a component is used — even a single vial of hyaluronidase — the kit must be restocked before the next patient is treated. The post-use restocking should be documented in the same log.
The Escalation Protocol
Having hyaluronidase is necessary but not sufficient. A defensible emergency response requires a written, practiced escalation protocol.
Step 1: Recognition
Stop injecting immediately if any of the following occur during or after HA filler injection:
- Skin blanching or pallor in the distribution of a named artery.
- Livedo reticularis (net-like purple/red mottling).
- Delayed or absent capillary refill (more than 2–3 seconds).
- Pain out of proportion to the injection, or pain developing in a distant area from the injection site.
- Skin discoloration progressing to a dusky gray or dark purple.
- Visual changes (blurred vision, vision loss, eye pain) — this indicates potential ophthalmic artery involvement and is an immediate emergency.
Step 2: Immediate Response
- Stop all injections. Remove needle or cannula.
- Notify the medical director or supervising physician immediately.
- Document the time of recognition.
- Photograph the affected area with a timestamp.
- Mark the borders of the ischemic area with a skin-marking pen.
- Reconstitute hyaluronidase: 150 units per vial × 10 vials = 1,500 units in 1 mL diluent (per CMAC protocol).
- Infiltrate hyaluronidase over the course of the affected artery and the wider ischemic area, using needle or cannula.
- Apply warm compresses and massage firmly to aid mechanical breakdown.
- Reassess capillary refill at 15–20 minutes. If perfusion has not been restored, re-dose hyaluronidase.
Step 3: Escalation
- Visual symptoms or periorbital involvement: Immediate referral to an ophthalmologist or emergency department. Ophthalmic artery occlusion can cause permanent blindness and requires specialist intervention.
- No improvement after 3–4 cycles of hyaluronidase: Arrange transfer to an emergency department. Consider hyperbaric oxygen referral.
- Signs of tissue necrosis developing (eschar, ulceration): Wound care referral. Continue hyaluronidase. Consider oral antibiotics for secondary infection prevention.
Step 4: Post-Event Documentation
Document in the patient's chart:
- Time of filler injection and product details (name, lot number, volume, site, technique).
- Time of recognition and clinical signs observed.
- Hyaluronidase administered: total units, number of doses, time of each dose.
- Clinical response after each dose (capillary refill, skin color, pain level).
- Referrals made and specialist response.
- Follow-up plan: the patient should be seen within 24–48 hours and potentially daily for the first 3–5 days to monitor for delayed tissue compromise.
- Patient instructions in writing: signs to watch for (worsening pain, expanding discoloration, visual changes), emergency contact number, and when to go to the ER.
Emergency Drills
Having a kit and a protocol is necessary but insufficient if no one has practiced using them. Dr. Tim Pearce, an aesthetic medicine educator who publishes extensively on vascular occlusion management, recommends that practices conduct emergency drills — simulated vascular occlusion scenarios where the team walks through the protocol in real time.
A drill should cover:
- Scenario presentation: A mock patient presents with blanching and pain in the nasolabial region 30 minutes after filler injection.
- Recognition: Every team member — including front desk staff — should know the signs that require immediate provider notification.
- Kit access: Time how long it takes to retrieve the kit, reconstitute hyaluronidase, and prepare for injection. If it takes more than 3–5 minutes, the kit location or organization needs to change.
- Role assignment: Who draws up the hyaluronidase? Who monitors the patient? Who calls the medical director? Who documents?
- Communication: Practice the escalation phone calls — to the medical director, the ophthalmologist, the emergency department.
Drills should be conducted at least quarterly for practices with multiple injectors, and whenever a new team member joins. Document each drill with the date, participants, scenario, and any identified gaps.
The Cost of Being Unprepared
A single-use vial of Hylenex costs approximately $40–60 in the U.S. A practice that stocks 20 vials invests roughly $800–1,200. A single vascular occlusion managed with in-house hyaluronidase within minutes of recognition may result in full recovery with no permanent damage.
A vascular occlusion that is not recognized, or is recognized but the practice has insufficient hyaluronidase on hand, can result in tissue necrosis requiring surgical reconstruction, permanent vision loss, or stroke. The malpractice claim that follows will allege that the practice was not prepared for a known, foreseeable complication of a procedure it chose to offer.
The kit is not optional. It is the standard of care for any practice that injects hyaluronic acid fillers.
Sources
- Alam M, et al. Rates of Vascular Occlusion Associated With Using Needles vs Cannulas for Filler Injection. JAMA Dermatology. 2021;157(2):174-180: https://jamanetwork.com/journals/jamadermatology/fullarticle/2774914
- Complications in Medical Aesthetics Collaborative (CMAC), "Guideline for the Management of Hyaluronic Acid Filler-induced Vascular Occlusion" (PMC, 2021): https://pmc.ncbi.nlm.nih.gov/articles/PMC8211329
- CMAC, "Guideline for the Safe Use of Hyaluronidase in Aesthetic Medicine, Including Modified High-dose Protocol" (JCAD, 2021): https://pmc.ncbi.nlm.nih.gov/articles/PMC8570661
- CMAC, "This Month's Guideline: The Use of Hyaluronidase in Aesthetic Practice (v2.4)" (PMC, 2018): https://pmc.ncbi.nlm.nih.gov/articles/PMC6011868
- American Med Spa Association, "How Safe Med Spas Manage Complications": https://www.americanmedspa.org/news/how-safe-med-spas-manage-complications
- Doctors of Nursing Practice, "Improving Compliance and Prevention in Vascular Occlusion Management" (DNP project): https://www.doctorsofnursingpractice.org/wp-content/uploads/project_form/abstract_150225075249.pdf
- Dr. Tim Pearce, "Emergency Kits for Managing Filler-Induced Vascular Occlusions": https://drtimpearce.com/2023/03/30/emergency-kits-for-managing-filler-induced-vascular-occlusions
- Air-Tite Products, "Creating a Vascular Occlusion Protocol": https://www.air-tite-shop.com/Articles/creating-a-vascular-occlusion-protocol
- MedSpa Standards, "Med Spa Emergency Protocol SOP Templates": https://medspastandards.com/emergency-protocols
- Hylenex (hyaluronidase human injection) Prescribing Information, Halozyme Therapeutics: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125426s056lbl.pdf
